N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-2,2-dimethyl-propionamide | 710322-83-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-2,2-dimethyl-propionamide
• 英文别名: N-[5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]pyrazin-2-yl]-2,2-dimethylpropanamide
• CAS: 710322-83-1
• 化学式: C₁₄H₂₁N₃O₃
• 分子量: 279.339
• InChiKey: RGARSQQYGHMKPG-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  73.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-2,2-dimethyl-propionamide 在 吡啶 、 盐酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 48.5h， 生成 (2R)-2-(3-chloro-4-(methylsulfonyl)phenyl)-N-(5-((S)-1,2-dihydroxyethyl)pyrazin-2-yl)-3-(3-oxocyclopentyl)propanamide
  参考文献：
  名称：

  Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes

  摘要：

  To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic ligand efficiency and demonstrated robust glucose lowering in diet-induced obese mice without a liability in predictive preclinical drug safety studies. Thus, it was selected as a clinical candidate and further studied in type 2 diabetic patients. Clinical data suggests no evidence of metabolite cycling, which is consistent with the preclinical profiling of metabolism.

  DOI：

  10.1021/ml400027y
• 作为产物：
  描述：

  N-[5-(2-Hydroxy-acetyl)-pyrazin-2-yl]-2,2-dimethyl-propionamide 在 glucose dehydrogenase 、 ketoreductase 对甲苯磺酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 4.5h， 生成 N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-2,2-dimethyl-propionamide
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF A GLUCOKINASE ACTIVATOR COMPOUND

  摘要：

  本发明涉及一种制备式I化合物的方法，其中R1为C1-6烷基，R2为氢或卤素。式I的(R)-2-苯基丙酸衍生物是合成式Xa的5-取代吡嗪或吡啶葡萄糖激酶激活剂的关键中间体，这些激活剂有可能用于治疗和/或预防II型糖尿病。

  公开号：

  US20110054174A1

文献信息

• [EN] 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE LA GLUCOKINASE A BASE DE PYRAZINE OU DE PYRIDINE SUBSTITUEES EN POSITION 5
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004052869A1

  公开（公告）日：2004-06-24

  The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

  本发明提供了一种化合物，其化学式为（I），其中取代基的定义在说明书中提供。还提供了包括符合化学式（I）的化合物的药物组合物，这些化合物是葡萄糖激酶激活剂，对于治疗2型糖尿病是有用的。
• BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE
  申请人：Hanlon Steven Paul

  公开号：US20080248537A1

  公开（公告）日：2008-10-09

  The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R 1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.

  本发明涉及生物催化不对称还原，用于制备2-氨基-[5-(1-羟基-2-羟基或卤代乙基)]-吡嗪衍生物，其化学式如下：其中R为较低的烷基羰基或氨基保护基，R1为羟基或卤素。这些化合物是一种葡萄糖激酶激活剂的制造中的关键中间体。
• [EN] PROCESS FOR THE PREPARATION OF A GLUCOKINASE ACTIVATOR COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ ACTIVATEUR DE GLUCOKINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011023706A1

  公开（公告）日：2011-03-03

  The present invention related to a process for the preparation of formula (I), wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen. (R)-2-phenyl propionic acid derivatives of the formula (I) are key intermediates in the synthesis of 5-substituted -pyrazine or pyridine glucokinase activators of the formula (Xa) as disclosed in PCT International Patent Application No. WO 2004/052869 A1, which have the potential to be useful as glucokinase activators are useful for the treatment and/or prophylaxis of type II diabetes.

  本发明涉及一种制备化合物（I）的方法，其中R1为C1-6-烷基，R2为氢或卤素。化合物（I）的(R)-2-苯基丙酸衍生物是5-取代吡啶或吡啶葡萄糖激酶激活剂合成中的关键中间体，如PCT国际专利申请号WO 2004/052869 A1所披露的，这些化合物具有潜力用作葡萄糖激酶激活剂，可用于治疗和/或预防II型糖尿病。
• 5-Substituted-six-membered heteroaromatic glucokinase activators
  申请人：——

  公开号：US20040147748A1

  公开（公告）日：2004-07-29

  The present invention provides a compound according to formula I 1 where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

  本发明提供了一种化合物，其化学式为I1，其中取代基的具体说明在规范中提供。还提供了包含化合物I的制药组合物。
• 5-substituted-six-membered heteroaromatic glucokinase activators
  申请人：Hoffmann-La Roche Inc.

  公开号：US07132425B2

  公开（公告）日：2006-11-07

  The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

  本发明提供了一个化合物，其化学式为I，其中置换基的定义在说明书中提供。还提供了包含化学式I的化合物的药物组合物。